Emedastina [INN-Spanish] en es it fr

Emedastina [INN-Spanish] Brand names, Emedastina [INN-Spanish] Analogs

Emedastina [INN-Spanish] Brand Names Mixture

  • No information avaliable

Emedastina [INN-Spanish] Chemical_Formula


Emedastina [INN-Spanish] RX_link


Emedastina [INN-Spanish] fda sheet

Emedastina_[INN-Spanish] FDA

Emedastina [INN-Spanish] msds (material safety sheet)

Emedastina [INN-Spanish] Synthesis Reference

No information avaliable

Emedastina [INN-Spanish] Molecular Weight

393.436 g/mol

Emedastina [INN-Spanish] Melting Point

No information avaliable

Emedastina [INN-Spanish] H2O Solubility

Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)

Emedastina [INN-Spanish] State


Emedastina [INN-Spanish] LogP


Emedastina [INN-Spanish] Dosage Forms

Tablet (27.3 mg, 109.3 mg or 163.9 mg)

Emedastina [INN-Spanish] Indication

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Emedastina [INN-Spanish] Pharmacology

Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.

Emedastina [INN-Spanish] Absorption

Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.

Emedastina [INN-Spanish] side effects and Toxicity

Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.

Emedastina [INN-Spanish] Patient Information

Emedastina [INN-Spanish] Organisms Affected

Humans and other mammals